Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

Modulation of death receptors by cancer therapeutic agents

(2010) Heath A. Elrod et al.   CANCER BIOLOGY & THERAPY

Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

(2009) C. H. Mom et al.   CLINICAL CANCER RESEARCH

Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study

(2009) Stephen Leong et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of a Triple Treatment with Irradiation, Agonistic TRAIL Receptor Antibodies and EGFR Blockade

(2009) Maximilian Niyazi et al.   STRAHLENTHERAPIE UND ONKOLOGIE

Stable XIAP knockdown clones of HCT116 colon cancer cells are more sensitive to TRAIL, taxanes and irradiation in vitro

(2008) Kate Connolly et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

BAG-1 is up-regulated in colorectal tumour progression and promotes colorectal tumour cell survival through increased NF-κB activity

(2008) Nadine K. Clemo et al.   CARCINOGENESIS

A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies

(2008) S. J. Hotte et al.   CLINICAL CANCER RESEARCH

TRAIL receptor-targeted therapeutics: Resistance mechanisms and strategies to avoid them

(2008) A THORBURN et al.   DRUG RESISTANCE UPDATES

Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas

(2008) Virginie Granci et al.   EUROPEAN JOURNAL OF CANCER

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer

(2008) F. Anthony Greco et al.   LUNG CANCER

Directing cancer cells to self-destruct with pro-apoptotic receptor agonists

(2008) Avi Ashkenazi   NATURE REVIEWS DRUG DISCOVERY

Combined inhibition of FLIP and XIAP induces Bax-independent apoptosis in type II colorectal cancer cells

(2008) T R Wilson et al.   ONCOGENE

p53-Mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells

(2008) F Toscano et al.   ONCOGENE

FLIP and the death effector domain family

(2008) J W Yu et al.   ONCOGENE

Bcl-xL and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells

(2008) Henning Schulze-Bergkamen et al.   WORLD JOURNAL OF GASTROENTEROLOGY